OBIO

Orchestra Biomed ($OBIO) Major Shareholder Buys $126,500 In Shares At Multi-Year Low Following FDA Approvals

04/29/2025 21:20

Roderick Wong, a major shareholder of Orchestra Biomed Holdings Inc ($OBIO), purchased 50,000 shares at $2.53 per share on April 29, 2025. This $126,500 investment comes amid a prolonged decline in the company's stock price over recent months. $OBIO shares have dropped dramatically from over $8.50 in mid-July 2024 to below $3 in early April 2025, and have recently been trading between $2.50 and $3.00. The broader U.S. market experienced significant volatility in the first week of April 2025 due to escalating trade tensions, during which $OBIO fell below the $3 mark. Wong's purchase coincides with positive regulatory developments for the company. Orchestra Biomed received FDA Breakthrough Device designation for its Avim therapy on April 22, 2025, followed by FDA approval of an Investigational Device Exemption (IDE) on April 29 to initiate a U.S. coronary pivotal trial for its first-in-class sirolimus-angioinfusion balloon, Virtue SAB. Roderick Wong, a physician and managing partner at RTW Investments, holds these shares through affiliated funds managed by RTW Investments. His substantial purchase signals insider confidence in the company's long-term value and potential despite the stock's recent poor performance. Prior to Wong's investment, other $OBIO executives demonstrated consistent buying patterns. David Hochman, an officer, made four separate purchases totaling over 20,000 shares between June and December 2024. He bought 1,000 shares at $6.95 on June 25, 2024; 2,500 shares at $5.84 on August 14; 10,000 shares between $4.76-$4.91 on September 24-25; and 9,000 shares between $4.66-$4.91 on December 18-23. This consistent buying amid a declining share price demonstrates strong insider confidence. CFO Andrew Lawrence Taylor also purchased 1,000 shares at $4.83 on December 19, 2024. While some executives sold shares during this period, those sales were primarily to cover tax obligations related to restricted stock unit (RSU) compensation, according to disclosure notes. Orchestra Biomed announced plans in August 2024 to potentially offer and sell up to $100 million in common stock. The company focuses on developing innovative medical devices for cardiovascular and hypertension treatments. The Virtue SAB trial is scheduled to begin in the second half of 2025 and represents a significant growth driver for the company. Currently a small-cap stock with a market capitalization of approximately $110 million, $OBIO has seen its valuation significantly reduced during its recent price decline. However, consecutive FDA positive decisions coupled with consistent insider buying suggest strong internal confidence in the company's technology and growth potential. As a common Wall Street adage suggests, insiders may sell their shares for many reasons, but they typically buy for only one – they expect the price to rise. The consistent purchases by major shareholders like Wong and top executives may indicate long-term investment value despite short-term price weakness. Investors would be wise to monitor $OBIO's upcoming clinical trial progress and regulatory approvals. While the current share price is at historical lows, successful commercialization of key products could offer significant upside potential.

You can receive notifications when news is published.